| Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. | |
| | |
MedLine Citation:
|
PMID: 17079534 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Postnatal corticosteroids were widely used in the 1990s in an attempt to reduce the incidence of bronchopulmonary dysplasia. However, high rates of short-term adverse effects and impaired neurodevelopmental outcomes were seen. In early 2002, a joint statement of the American Academy of Pediatrics and Canadian Paediatric Society called for limitation in the use of postnatal corticosteroids. The impact of this statement is not known. OBJECTIVES: The purpose of this work was to determine the frequency of postnatal corticosteroid use and mortality and morbidities over time, particularly before and after the joint statement. DESIGN/METHODS: We conducted a retrospective analysis of cohort data within 3 large network registries (the National Institute of Child Health and Development Neonatal Research Network [18 centers], the Vermont Oxford Network [444 centers], and the Canadian Neonatal Network [10 centers]) for the following 3 periods: prestatement (2001), statement (2002), and poststatement (2003) of very low birth-weight infants (501-1500 g). The National Institute of Child Health and Development Neonatal Research Network and the Vermont Oxford Network were also analyzed for longer-term trends from 1990 to 2003. Postnatal corticosteroid use, mortality at discharge, and neonatal morbidities (bronchopulmonary dysplasia at 36 weeks, late-onset infection >72 hours of age, necrotizing enterocolitis treated with surgery, and length of stay) between periods were compared. RESULTS: Mean birth weight (range: 1022-1060 g), postmenstrual age (28 weeks), and gender (51% male) were similar between the networks. Race differed with more black infants in the National Institute of Child Health and Development Neonatal Research Network than the Vermont Oxford Network (38% vs 24%). Antenatal steroid use was similar (range: 61%-75%). Postnatal corticosteroid use rose from 1990 (8%-16%), peaked in 1996-1998 (24%-28%), and began to decline in 1999. Use in 2003 was significantly less than in 2001. Mortality and major morbidities were similar. CONCLUSIONS: Postnatal corticosteroid use had decreased significantly in 3 large neonatal networks before the joint statement with further decreases after the statement with no apparent impact on mortality and short-term morbidity. Despite substantial decreases, approximately 8% of very low birth-weight infants continue to be treated with postnatal corticosteroid. |
| | |
Authors:
|
Michele C Walsh; Qing Yao; Jeffrey D Horbar; Joseph H Carpenter; Shoo K Lee; Arne Ohlsson |
Related Documents
:
|
9425374 - Morbidity and growth performance of infants in madura, indonesia. 11101024 - Epidemiology and predictors of infant morbidity in rural malawi. 21696814 - Effect of a partially hydrolyzed whey infant formula at weaning on risk of allergic dis... 10807224 - Physiology of infants with very low birth weight. 11014314 - Atypical hypothyroidism and the very low birthweight infant. 8825694 - "menstrual" migraine: towards a definition. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Pediatrics Volume: 118 ISSN: 1098-4275 ISO Abbreviation: Pediatrics Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-11-02 Completed Date: 2006-11-14 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0376422 Medline TA: Pediatrics Country: United States |
Other Details:
|
Languages: eng Pagination: e1328-35 Citation Subset: AIM; IM |
Affiliation:
|
Neonatal Research Network, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. michele.walsh@case.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use* Bronchopulmonary Dysplasia / drug therapy* Drug Utilization / statistics & numerical data Female Humans Infant, Newborn Male Retrospective Studies |
| Grant Support | |
ID/Acronym/Agency:
|
U01 HD36790/HD/NICHD NIH HHS; U10 HD21364/HD/NICHD NIH HHS; U10 HD21373/HD/NICHD NIH HHS; U10 HD21385/HD/NICHD NIH HHS; U10 HD21397/HD/NICHD NIH HHS; U10 HD27851/HD/NICHD NIH HHS; U10 HD27853/HD/NICHD NIH HHS; U10 HD27856/HD/NICHD NIH HHS; U10 HD27871/HD/NICHD NIH HHS; U10 HD27880/HD/NICHD NIH HHS; U10 HD27904/HD/NICHD NIH HHS; U10 HD34216/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Direct medical cost of influenza-related hospitalizations in children.
Next Document: Illness and injury among children attending summer camp in the United States, 2005.